

CERTIFICATE UNDER 37 CFR § 1.10 OF MAILING BY "EXPRESS MAIL"


EV 758328329 US

November 5, 2007

USPS Express Mail Label Number

Date of Deposit

I hereby certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By 

Lynne Millot

DS Form PTO/SB/08: Substitute for form 1449A/PTO

Complete if Known


INFORMATION DISCLOSURE STATEMENT BY APPLICANT
 NOV 05 2007
 (Use as many sheets as necessary)

Sheet 1 of

Application Number	10/748,112
Filing Date	December 29, 2003
First Named Inventor	Sanjay D. KHARE
Art Unit	1644
Examiner Name	Ilia I. OUSPENSKI
Attorney Docket Number	06843.0052-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No.	Document Number	Issue or Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)	MM-DD-YYYY		

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code Number Kind Code (if known)				

NONPATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
		EMERY et al., "Improvement in health-related quality of life in patients with active rheumatoid arthritis: CTLA4 Ig combined with etanercept compared to etanercept plus placebo," <i>Arthritis Rheum.</i> , 46:S514, 1376, Abstract (2002).	
		BENDELE et al., "Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis," <i>Arthritis & Rheumatism</i> , 43:2648-2659 (2000).	
		FELDMANN et al., "Anti-TNF α therapy of rheumatoid arthritis: What have we learned?," <i>Annu. Rev. Immunol.</i> , 19:163-196 (2001).	
		HARACUI et al., "Biologic agents in the treatment of rheumatoid arthritis," <i>Current Pharmaceutical Biotechnology</i> , 1:217-233 (2000).	
		LORENZI et al., "Biologics agents: a novel approach to the therapy of rheumatoid arthritis," <i>Exp. Opin. Invest. Drugs</i> , 9:1479-1490 (2000).	
		LU et al., "Effects of virus expressing CTLA4-IG and IL1-RA on islet Xenografts," <i>Transplantation Proceedings</i> , 33:713-714 (2001).	
		MORELAND et al., "Biological agents for treating rheumatoid arthritis," <i>Arthritis & Rheumatism</i> , 40:397-409 (1997).	
		TOTSUKA et al., "Therapeutic effect of anti-OX40L and anti-TNF- α MAbs in a murine model of chronic colitis," <i>Am.J.Physiol Gastrointest.Liver Physiol.</i> , 284:G595-G603 (2003).	
		YOSHIOKA et al., "Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis," <i>Eur J. Immunol.</i> , 30:2815-2823 (2000).	
		WEINBERG et al., "Antibodies to OX-40 (CD134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease," <i>Molecular Medicine Today</i> , 4:76-83 (1998).	
		WEINBLATT et al., "A pilot, multi-center, randomized, double-blind, placebo controlled of a co-stimulation blocker CTLA4-Ig (2 mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis," <i>Arthritis Rheum.</i> , 46:S204, 464, Abstract (2002).	
		WILLIAMS et al., "Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis," <i>Proc. Natl. Acad. Sci. USA</i> , 91:2762-2766 (1994).	
		Supplementary Partial European Search Report dated August 13, 2007, in European Patent Application No. 03800236.6 - 2406	

Examiner Signature	/ilia Ouspenski/	Date Considered	02/06/2008
--------------------	------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.O./